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ORIGINAL ARTICLEProglucagon-Derived Peptides Do Not Significantly
Affect Acute Exocrine Pancreas in RatsElina Akalestou, PhD,* Ioannis Christakis, FRCS,* Antonia M. Solomou, MSc,† James S. Minnion, PhD,*
Guy A. Rutter, PhD,† and Stephen R. Bloom, FRS*Objectives: Reports have suggested a link between treatment with
glucagon-like peptide 1 (GLP-1) analogs and an increased risk of pancrea-
titis. Oxyntomodulin, a dual agonist of both GLP-1 and glucagon recep-
tors, is currently being investigated as a potential antiobesity therapy, but
little is known about its pancreatic safety. The aim of the study was to
investigate the acute effect of oxyntomodulin and other proglucagon-
derived peptides on the rat exocrine pancreas.
Methods: Glucagon-like peptide 1, oxyntomodulin, glucagon, and
exendin-4 were infused into anesthetized rats to measure plasma amylase
concentration changes. In addition, the effect of each peptide on both am-
ylase release and proliferation in rat pancreatic acinar (AR42J) and pri-
mary isolated ductal cells was determined.
Results: Plasma amylase did not increase postpeptide infusion, com-
pared with vehicle and cholecystokinin; however, oxyntomodulin in-
hibited plasma amylase when coadministered with cholecystokinin. None
of the peptides caused a significant increase in proliferation rate or amy-
lase secretion from acinar and ductal cells.
Conclusions: The investigated peptides do not have an acute effect on
the exocrine pancreas with regard to proliferation and plasma amylase,
when administered individually. Oxyntomodulin seems to be a potent in-
hibitor of amylase release, potentially making it a safer antiobesity agent re-
garding pancreatitis, compared with GLP-1 agonists.
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P roglucagon-derived peptide glucagon-like peptide 1 (GLP-1)receptor agonists, such as the Food and Drug Administration–
approved exenatide and liraglutide, are widely used in the treat-
ment of type 2 diabetes because of their ability to induce
glucose-stimulated insulin secretion, also known as the incretin
effect, as well as their beneficial weight-lowering properties. Pan-
creatic safety became a subject of debate when a number of case
reports linked the use of incretin therapies to pancreatitis. Sub-
sequently, a number of postmarketing studies were published
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Pancreas • Volume 45, Number 7, August 2016pancreata from organ donors with type 2 diabetes treated with
incretin therapy demonstrated an increase in pancreatic size ac-
companied with elevated ductal proliferation and dysplasia.7
However, a number of chronic studies in rodents and nonhuman
primates found no association between incretin therapies and pan-
creatic abnormalities.8–14 The discrepancy might be explained by
confounding factors such as high-fat diet and type 2 diabetes
contributing to the development of pancreatitis, irrespective of
the use of incretin-based medications.15,16 Indeed, in July 2013,
the European Medicines Agency's Committee for Medicinal Pro-
ducts for Human Use and the Food and Drug Administration
concluded that the data available did not indicate an increased in-
cidence of pancreatitis with GLP-1 receptor agonists and the ben-
efits of their use in patients with type 2 diabetes outweighed any
possible risks.17
However, GLP-1 analogs are currently undergoing regulatory
evaluation for use as weight loss agents in obese people without di-
abetes, increasing the target population of patients potentially eligi-
ble for treatment.18 Oxyntomodulin is another proglucagon-derived
peptide, which acts at both GLP-1 and glucagon receptors. It has
been demonstrated to have beneficial effects on energy homeostasis
via reduction of food intake and increase in energy expenditure in
rodents and in man, and its therapeutic potential in the treatment
of obesity is currently being assessed.19–26 However, little is known
about the pancreatic safety of this peptide.
The aim of the study was to evaluate the acute effect of
oxyntomodulin and other proglucagon-derived peptides including
GLP-1 and glucagon, as well as the GLP-1 analog exendin-4, on
the exocrine pancreas and potentially provide additional informa-
tion on their safety. To that end, in vivo and in vitro peptide-
induced amylase secretion, as well as peptide-induced acinar and
ductal proliferation, was assessed in the rat model.
METHODS
Study of Plasma Amylase Release In Vivo
Animals
All animal procedures undertaken were approved by the
British Home Office under the UK Animal (Scientific Proce-
dures) Act 1986. Adult male Wistar rats (Charles River Ltd,
Margate, Kent, United Kingdom) weighing 300 to 500 g were
maintained under controlled temperature (21°C–23°C) and
lights (12:12-hour light-dark schedule, lights on at 7:00 A.M.).
Animals were fasted for 18 hours before the experiment while
allowed ad libitum access to water.
Procedure
The GLP-1, glucagon, oxyntomodulin, and exendin-4 were
purchased from Bachem, Ltd (Merseyside, United Kingdom).
Gelofusine was used as the vehicle. CCK8 (Sigma-Aldrich, Dorset,
United Kingdom), the main stimulus to amylase secretion from
the exocrine pancreas, was used as a positive control. Animals
were anesthetized with isoflurane at 1.5% to 2% flow rate. The
technical aspects of the operation have been previouslywww.pancreasjournal.com 967
Akalestou et al Pancreas • Volume 45, Number 7, August 2016described by Christakis et al.27 A catheter was introduced into
the left femoral vein to introduce a 30 nmol bolus injection of pep-
tide. To avoid sample contamination, the route of injection was
different to the route of sampling. The dosewas based on previous
unpublished studies performed in the laboratory to achieve detect-
able levels of each peptide and is 6.25-fold higher than the average
therapeutic dose of exendin-4, to maximize the potential side ef-
fect. The procedure length and sampling times were chosen to de-
tect early amylase release post-CCK administration and to cover
the maximum time spectrum of potential amylase release in re-
sponse to peptide injection. Blood sampleswere collected through
another catheter placed in the right jugular vein. The catheters
used were polyethylene tubing (internal diameter, 0.46 mm; out-
side diameter, 0.91 mm) (Instech, Solomon, Pa). The operating
time for cannulation of the jugular and femoral vein and the unex-
pected events were recorded in a database. Glucose levels were
measured before and during operation to monitor animal stress.
At the end of the experiment, animals were killed by CO2 inhala-
tion and neck dislocation (Schedule 1 method under the Animals
[Scientific Procedures] Act 1986).
Sampling
Two baseline samples were obtained from the jugular vein be-
fore peptide injection. Postinjection, a 0.1 mL-sample was obtained
every 2 minutes for the first 10 minutes, then at 15 minutes, and
every 10minutes until 50 minutes. Total blood volumewithdrawn
was within recommended volume limits. Plasma amylase activity
was determined using an Amylase assay kit (Abcam, Cambridge,
United Kingdom) according to the manufacturer's instructions.
Study of Amylase Secretion In Vitro
The rat pancreatic acinar cell lineAR42Jwas purchased from
Sigma-Aldrich. AR42J cells were routinely maintained in RPMI
1640 media, supplemented with 10% foetal bovine serum (FBS),
100 IU/mL penicillin, 100 μg/mL streptomycin, and 2 mM gluta-
mine (Sigma-Aldrich). Cells were incubated with 20 nM dexa-
methasone for 48 hours before secretion assay to induce CCK
responsivity, as described by Logsdon et al.28 Cells from passage
11 to 18 were used throughout this study and were routinely incu-
bated in a humidified incubator at 37°C with 95% air and 5%CO2.
To assess amylase secretion, cells were plated at approxi-
mately 105 cells/mL onto 24-well plates (500 μL/well) 24 hours
before the experiment. Immediately before treatment, cells were
washed with 0.1 M phosphate buffered saline. Cells were treated
for 50 minutes at 37°C with ascending concentrations of the
peptides diluted in serum-free RPMI 1640 media. After this,
cells were similarly treated with 10 nM of each investigated pep-
tide and CCK. The dose was in agreement with previously pub-
lished research.29,30 The incubation medium was collected and
cells were lysed. Lysates were collected for total amylase content.
Amylase secretion was then quantified as a percentage of amylase
activity in incubation medium compared with total activity (incu-
bation medium plus lysate) using an Amylase assay kit (Abcam)
according to the manufacturer's instructions.
Primary Isolation of Epithelial Pancreatic Duct Cells
Rats were killed using a Schedule 1 method under the Ani-
mals (Scientific Procedures) Act 1986. An abdominal midline in-
cision was performed to expose the contents of the abdominal
cavity. By displacing the liver superiorly and the intestine inferi-
orly, the duodenum was accessible. Curved dissecting scissors
were used to isolate and dissect the pancreas free from its attach-
ments to the duodenum and the rest of the abdominal organs.
The organ was then transferred to a 6-cm tissue culture dish with968 www.pancreasjournal.comice-cold Leibovitz (Gibco, Paisley, United Kingdom). Using a dis-
secting microscope, the surrounding pancreatic tissue was cleaned
away and the duct was transferred in a tube containing 5 mL of
collagenase XI (Sigma-Aldrich) solution for 12 minutes. After in-
cubation, the remaining fibroblasts were removed and the treat-
ment is repeated. The biliopancreatic duct in rat is a distinct
structure under the dissecting scope, which ensures that it neatly
isolated with minimum contamination of surrounding tissue.
The ductal cells were isolated as previously described by
Chen et al.31,32 To dissociate ductal cells from the extracellular
matrix, the ducts were incubated with dispase solution (Sigma-
Aldrich). To dissociate the duct into cellular aggregates, it was
subjected to a series of trypsinization steps, each one stopped by
adding 0.5 mL of ice-cold FBS. The collected fractions were
then centrifuged and the resulting pellet was resuspended in
pancreatic medium (1:1 Hams F12/DMEM, 100 ng/mL cholera
toxin, 100 μg/mL soybean trypsin inhibitor, 20% FBS, penicillin
100 IU/mL, and streptomycin 100 mg/mL) plated in MaxGel
ECM (Sigma-Aldrich) matrix coated wells in 6-well plates and in-
cubated at 37°C and at 5% CO2.
RNA Extraction and Quantitative Polymerase
Chain Reaction in AR42J and Ductal Cells
Cells were cultured 2 hours postisolation to ensure maximum
viability and replication detection, in the presence or absence of
10 nM of each peptide for 18 hours. Medium was changed every
9 hours. Peptides were diluted in RPMI 1640 (AR42J) or pancre-
atic (ductal) medium, supplementedwith 2% FBS. Total RNAwas
isolated from AR42J cells using TRI Reagent (Sigma-Aldrich) by
referring to the manufacturer's protocol. 1-Bromo-3-chloropropane
(Sigma-Aldrich) was added to precipitate the total RNA and the
extracted RNA pellet was then washed with 75% ethanol. RNA
was purified using PureLink RNA kit and DNA was digested
from total RNA using PureLink DNase (Thermo Fisher Scien-
tific, Paisley, United Kingdom). The purified RNAwas dissolved
in RNase and DNase free distilled water (Thermo Fisher Scien-
tific) and was immediately stored at −80°C until further analysis.
Complementary DNAwas synthesized from total RNAwith
High-Capacity cDNA Reverse Transcription Kit (Thermo Fisher
Scientific) according to the protocol recommended by the manu-
facturer. The protocol conditions were 10 minutes at 25°C for
primer annealing, 120 minutes at 37°C for reverse transcription,
and 5 minutes at 85°C. Quantitative Polymerase Chain Reaction
(PCR) analysis was used to quantify the expression level of prolif-
eration marker Ki-67. For the detection of Ki-67, QPCR primers,
which crossed a splice junction, were designed using Primer Ex-
press (Invitrogen, Paisley, United Kingdom; Table 1). The expres-
sion levels were measured using a 7500 Fast Real-Time PCR
System (Applied Biosystems, Paisley, United Kingdom). The reac-
tion mixture contained 6 μL of Fast SYBR Green Master Mix
(Invitrogen), 0.35 μL of each primer (10 μM, Thermo Fisher Scien-
tific), 3 μL of water, and 2 μL of cDNA in a final volume of 12 μL.
Sampleswere amplified in duplicates. The reactionwas startedwith
2 minutes at 50°C followed by the activation and predenaturation
step at 95°C for 10 minutes. The reaction run consisted of 40 cy-
cles comprising 15 seconds at 95°C and 1 minute at 60°C.
Data Analysis
Data are presented as mean (SEM). All reported P values
were based on 2-sided tests. Student t test with Bonferroni correc-
tion was used in all experiments and 1-way analysis of variance
with Tukey post hoc test was used to compare amylase secretion
levels of peptide-treated AR42J cells against untreated control
group. Ki-67 mRNA data were normalized against β-actin levels.© 2016 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 1. Primers Used for the Quantitative Detection of Ki-67, β-Actin
Analysed Transcript Sequence of Forward Primer Sequence of Reverse Primer
Ki-67 TTGACCGCTCCTTTAGGTATGAA GGTATCTTGACCTTCCCCATCA
β-Actin CGAGTCGCGTCCACCC CATCCATGGCGAACTGGTG
Pancreas • Volume 45, Number 7, August 2016 Proglucagon Peptides Effect on Exocrine PancreasThe analytical method used was 2(−Delta Ct). The level of statis-
tical significance was set at a P value of less than 0.05. Prism 5.01
(GraphPad Software Inc, San Diego, Calif ) statistical software
was used for all statistical analysis.
RESULTS
Study of Amylase Secretion In Vivo
A small percentage of amylase that is released in the gut leaks
into the bloodstream and its concentration can be used as indicator
of pancreatitis. To assess any pathogenic effect of peptides on the
exocrine pancreas, rats were infused with GLP-1, exendin-4, glu-
cagon, or oxyntomodulin, and plasma amylase levels were deter-
mined at regular time intervals. Cholecystokinin was used as a
positive control at a 2.4 nmol/rat dose that could induce significant
amylase secretion. The generated curve is used as a comparison in
Figures 1 and 2. Rats treated with CCK demonstrated an almost
2-fold increase in plasma amylase during the 50-minute postinjec-
tion period (Figs. 1A, B). Cholecystokinin increased plasma amylaseFIGURE 1. A and B, Amylase secretion (U/L) post–GLP-1, glucagon (GC
30 nmol intravenous injection. A dose of 2.4 nmol/rat cholecystokinin (C
correctionwas used to evaluate differences across time points versus time 0
0 basal sample (n = 4–5).
© 2016 Wolters Kluwer Health, Inc. All rights reserved.significantly from 30 minutes onward compared with time 0
(P < 0.01), reaching approximately 18.00 (0.70) U/L. Plasma
amylase concentration did not increase post–GLP-1, glucagon,
oxyntomodulin, or exendin-4 intravenous injection, compared
with basal amylase and vehicle controls. No significant increase
in plasma amylase was observed after treatment with the rest of
the peptides and the vehicle as amylase levels reached approxi-
mately 12.00 (0.21) U/L throughout the 50 minutes of sampling
(Figs. 1A, B). Average basal amylase was 10.50 (0.39) U/L for
all groups (n = 4–5).
The effect of each peptide on plasma amylase levels given in
combination with CCK was assessed. Coadministration of GLP-
1, exendin-4, and glucagon with CCK did not inhibit plasma am-
ylase compared with CCK alone (Fig. 2A), with plasma amylase
levels increasing from 9.8 (0.37) to 17.52 (0.94) U/L for all
groups (n = 4–5). However, oxyntomodulin suppressed CCK-
induced amylase release by approximately 3.4 (0.5) U/L on aver-
age, when coadministered with CCK (Fig. 2B, n = 5, P < 0.01).
Significant inhibition was achieved both in the beginning of
sampling at 6 and 8 minutes and the end at 30 and 50 minutes.G), oxyntomodulin (OXM), and exendin-4 (Ex-4) bolus
CK) was infused intravenously. Student t test with Bonferroni
. Values are shown asmean (SEM). †P < 0.01, ***P < 0.001 versus time
www.pancreasjournal.com 969
FIGURE 2. A and B, Amylase secretion (U/L) postpeptide and CCK intravenous coadministration as a single bolus injection.
The GLP-1, glucagon (GCG), oxyntomodulin (OXM), and exendin-4 (EX-4) were coadministered at 30 nmol with 2.4 nmol CCK.
Student t test with Bonferroni correction was used between groups at individual time points versus CCK. Values are shown as mean(SEM).
#P < 0.05, ##P < 0.01 versus CCK (n = 4–5).
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AR42J cells, an in vitro model of the exocrine pancreas, were
treated with GLP-1, glucagon, oxyntomodulin, exendin-4, and
CCK. Total amylase and secreted amylase levels were measured
after 50 minutes of incubation. Treatment of AR42J cells with
CCK, a known stimulant of amylase release, resulted in a dose-
responsive secretion of amylase, reaching 28% of total amylase
activity in 50 minutes (Fig. 3, n = 5, P < 0.001). The GLP-1,
exendin-4, glucagon, and oxyntomodulin did not induce amylase
secretion at any of the doses tested, because amylase levels re-
mained stable at 13.8 (0.45%) of total, the same as untreated cells.
Coadministration of CCK (1 nM) with each peptide (10 nM) re-
sulted in a nonsignificant trend of an inhibition of CCK-induced
amylase secretion (Fig. 4).Cell Proliferation in AR42J and Biliopancreatic
Ductal Cells
Existence of GLP-1 and glucagon receptors on AR42J and
biliopancreatic ductal cells was confirmed by competitive receptor
affinity studies (data not shown). To determine whether the test
peptides had an effect on the rate of cellular proliferation, AR42J
and ductal cells were treated with 10 nM of GLP-1, glucagon,
oxyntomodulin, and exendin-4 for 18 hours. After treatment,
mRNAwas extracted and the level of proliferation marker Ki-67
was analyzed using quantitative PCR (Figs. 5A, B). Quantitatively,
compared with the untreated control cells, the test peptide did not
cause a significantly higher expression of Ki-67 (P > 0.05).970 www.pancreasjournal.comDISCUSSION
Our experiments focused on 4 peptides, which have been
identified as potential therapeutic agents for the treatment of obe-
sity and type 2 diabetes, with regard to pancreatic safety. A num-
ber of preclinical chronic safety studies have been completed in
rodents and nonhuman primates to investigate findings of incretin
peptides and DPP-IV long term. However, relatively little is
known about the actions of incretin peptides on the exocrine
pancreas. Incretins have been hypothesized to cause pancreatic
ductal and acinar cell hyperplasia and inflammation in the exo-
crine pancreas.7,33,34 On the other hand, glucagon has been previ-
ously suggested to inhibit gastric release, a fact that made it a
potential peptide for the treatment of pancreatitis in the past.35
Amylase plasma concentration increase in pancreatitis is a
result of pancreatic enzyme leakage from damaged acinars. In a
CCK-induced pancreatitis model in rat, hyperamylasemia was
detected 30 minutes posttreatment, whereas acinar damage and
pancreatic edema was observed after 60 minutes.36 Here, we
demonstrated no change in amylase release in response to ad-
ministration of GLP-1, glucagon, exendin-4, and oxyntomodulin,
alone, in vivo and in vitro. Similarly, GLP-1, glucagon, and
exendin-4 coadministration with CCK did not mitigate against
the CCKinduced increase in amylase concentration. However,
coadministration of oxyntomodulin and CCK caused a significant
inhibition of CCK-induced plasma amylase release in vivo, com-
pared with CCK alone.
A number of invivo studies have been performed, evaluating the
effect of constant infusion of GLP-1, glucagon, and oxyntomodulin© 2016 Wolters Kluwer Health, Inc. All rights reserved.
FIGURE 3. Amylase release from AR42J cells post–GLP-1, glucagon, oxyntomodulin, exendin-4, and CCK treatment at ascending
concentrations for 50minutes (n = 5) A,GLP-1. B, Glucagon. C,Oxyntomodulin. D, Exendin-4. E, CCK. Amylase is expressed as a percentage
of the secreted amylase into themedium over the total amylase content of the cells (100%). One-way analysis of variance with Tukey post hoc
test was used. Values are shown as mean(SEM). *P < 0.001 versus untreated cells (0).
Pancreas • Volume 45, Number 7, August 2016 Proglucagon Peptides Effect on Exocrine Pancreasin lower doses in direct pancreatic secretion through bile
duct cannulation. Investigations have shown that both glucagon
and oxyntomodulin are known to inhibit gastric release, with
oxyntomodulin being 10 times more potent than glucagon in this
regard, potentially because of its tissue specificity at the gastroin-
testinal tract, compared with glucagon, which is more specific to
the liver.30,37,38 In previous studies in the anesthetized rat, basalFIGURE 4. Amylase release from AR42J cells postpeptide (10 nM)/CCK (
percentage of the secreted amylase into the medium over the total activ
was used between CCK and peptides. Values are shown as mean(SEM).
© 2016 Wolters Kluwer Health, Inc. All rights reserved.pancreatic secretion could not be inhibited by oxyntomodulin in-
fusion, yet when stimulated with a CCK agonist, pancreatic secre-
tion levels decreased. During these studies, an oxyntomodulin
effect through vagal afferents was hypothesized, as in physiologic
doses of CCK8, afferent messages transmitted in the central ner-
vous system were produced before the observation of an efferent
vagal transmission to the rat pancreas.39 It has been suggested that1 nM) treatment for 50 minutes (n = 5). Amylase is expressed as a
ity of the cells (100%). Student t test with Bonferroni correction
#P < 0.05, ##P < 0.01, ###P < 0.001 versus CCK.
www.pancreasjournal.com 971
FIGURE 5. Relative Ki67 mRNA expression in AR42J cells (A)
and biliopancreatic ductal cells (B) treated with GLP-1, glucagon
(GCG), oxyntomodulin (OXM), and exendin-4 (Ex-4) for 18 hours
(n = 3–4). Student t test with Bonferroni correction was used
between untreated control group and peptides. Values are
shown as mean(SEM).
Akalestou et al Pancreas • Volume 45, Number 7, August 2016a possible mechanism of this oxyntomodulin function is through
the activity of gastropancreatic intrinsic nerves or by pregangli-
onic inhibition of excitatory vagal fibers via the central nervous
system.30,40 Nonetheless, the exact mechanism through which
oxyntomodulin inhibits CCK8-induced pancreatic secretion,
whereas glucagon does not, remains unclear. This study con-
firmed the inhibitory function of oxyntomodulin, previously
shown in overall gastric secretion, and cross-examined whether
this effect extends to GLP-1 and exendin-4 using plasma amylase
measurement.
It has previously been shown that pancreatic ductal cell pro-
liferation is elevated in both obese and diabetic patients, which
can predispose pancreatitis, possibly because of the buildup of ex-
cessive fat in pancreatic tissue, resulting in β-cell apoptosis and
inflammation.34 Because β-cell numbers decrease in type 2 diabe-
tes, it has been suggested that islet regeneration is attempted
through duct-related progenitors and proliferation rate is enhanced
by GLP-1, causing blockages in the pancreatic duct,41 potentially
through phosphorylation of cAMP response element-binding pro-
tein and stimulation of mitogen-activated protein kinases path-
way,33 whereas Immediate Early Genes egr-1 and c-fos were also
investigated.8 Nonetheless, in this work, GLP-1 and exendin-4
did not increase pancreatic acinar or ductal cell proliferation rate
when compared with untreated cells during the course of 18 hours.
AR42J cells are currently the only cell line that maintains a
number of normal pancreatic acinar cell characteristics, when in972 www.pancreasjournal.comculture, such as the synthesis and secretion of digestive enzymes
protein expression and receptor expression similar to pancreatic ac-
inars. AR42J cells, used in this study, are derived from a chemi-
cally induced exocrine pancreatic tumor; therefore, these are not
grown from a single clone and can present response differences.42
Even so, our results are in agreement with previous studies that
used both AR42J and isolated rat acini treated with GLP-1 and ex-
pand the investigated effect to oxyntomodulin and glucagon.29,30,43
Taken together, our results indicate that GLP-1 and
exendin-4 do not have an acute effect on exocrine pancreatic re-
lease, in the in vivo and in vitro models tested. Further studies in
diabetic or obese rat models should be performed to determine
whether failure to observe an acute effect persists in these disease
states. Our finding that oxyntomodulin protects against the CCK-
induced increase in the appearance of pancreatic enzymes in the
blood in vivo supports a favorable pancreatic safety profile for
this peptide, because it could be protective in cases of type 2
diabetes-induced pancreatitis. The fact that this observation was
not replicated in vitro might suggest that the peptide might not
be damaging or acting directly on acinar cells, with one possibil-
ity being this effect is mediated via vagal innervation.30 Because
oxyntomodulin is a dual GLP-1/glucagon receptor agonist, the
finding that neither GLP-1 nor glucagon alone produced this ef-
fect is interesting and merit further investigation. Furthermore,
longer-term studies need to be performed to further understand
the effect of this peptide on pancreatic exocrine tissue and will
be critical if this peptide is to be used as a weight loss agent in
the future.
Because the use of GLP-1 receptor agonists for the treatment
of obesity has been licensed,18 it is likely that there will be a rapid
increase in the number of patients taking this class of medication.
Although numerous long-term safety pharmacology studies have
been completed and pharmacovigilance systems are in place,
questions remain regarding the pancreatic safety of this drug class.
Dual GLP-1 and glucagon receptor agonists are also underdevel-
opment as obesity treatments. In this study, we found an inhibitory
effect of oxyntomodulin on the CCK-induced increase in the ap-
pearance of pancreatic enzyme in blood, which might support that
it could be useful in the treatment of diabetic obese patients, be-
cause it can have a protective effect against diabetes-induced pan-
creatic inflammation, in addition to weight loss induction.
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